logo
Health Canada Approves Lilly's Omvoh® (mirikizumab) for Crohn's Disease; New Citrate-Free Formulation Français

Health Canada Approves Lilly's Omvoh® (mirikizumab) for Crohn's Disease; New Citrate-Free Formulation Français

Cision Canada15-07-2025
Omvoh ® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn's disease (CD)
In VIVID-1, Omvoh ® showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately to severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints. 3
Health Canada has also approved a new citrate-free formulation of Omvoh ® for subcutaneous injection, which contains the same active ingredients as the original Omvoh ®.
TORONTO, July 15, 2025 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh ® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh ® is an interleukin-23p19 antagonist for the treatment of adult patients with moderately to severely active CD who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment. 1 Health Canada has also approved a new citrate-free formulation of Omvoh ® for subcutaneous injection, for the existing UC indication, as well as the new CD indication.
"We are pleased to see that Omvoh ® will now be able to provide people living with moderately to severely active CD an effective and safe option for treatment," said Mathilde Merlet, President and General Manager of Lilly Canada. "With this additional indication, we are reinforcing our commitment to helping more of the IBD community. Additionally, we are proud to be able to introduce a new citrate-free formulation, which we hope will improve the patient experience, while offering the same quality, efficacy, and safety that patients are accustomed to."
The authorization of Omvoh ® for CD was based on results from the VIVID-1 clinical study, which included over 1,000 adults. In VIVID-1, mirikizumab showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately-to-severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints. The coprimary composite endpoints included patient-reported outcome (PRO) clinical response at week 12 and endoscopic response at week 52 (endoscopic response-composite), and PRO clinical response at week 12 and Crohn's Disease Activity Index (CDAI) clinical remission at week 52 (CDAI clinical remission-composite). Endoscopic response-composite was reached in 220 (38%) of 579 patients on mirikizumab versus 18 (9%) of 199 patients on placebo; CDAI clinical remission-composite was reached in 263 (45%) of 579 patients on mirikizumab versus 39 (20%) of 199 patients on placebo. Statistical significance was also observed in subgroups with and without failure to biological therapies for coprimary endpoints and most major secondary endpoints. 3
The Community Reacts:
Sylvain Chiasson, Interim President & CEO of Crohn's and Colitis Canada:
"Crohn's and Colitis Canada always welcomes new treatments for people with CD in Canada. CD is a chronic autoimmune disease where the immune system attacks the gastrointestinal system. CD is a complex disease that is debilitating, leads to hospitalizations and surgeries, and has a tremendous impact on the quality of life for the approximately 162,000 Canadians living with this disease. Because of the disease's complexity, not all people with CD respond in the same way to the available treatments. So, it is welcome news for Crohn's and Colitis Canada when there is a new therapy available for people with CD."
Gail Attara, Chief Executive Officer of the Gastrointestinal Society (www.badgut.org):
"We are so pleased to learn that Health Canada has approved a CD indication for Omvoh (mirikizumab). Compared to other inflammatory conditions, CD has very few medications, so the introduction of Omvoh's expanded use as a new option is excellent news for the IBD community."
Dr. John Marshall, Professor of Medicine, and Director of the Division of Gastroenterology at McMaster University:
"It is exciting to see a new and highly effective therapy being made available for people living with CD. Clinical trials have shown mirikizumab to be both safe and effective, and this will be an appealing treatment option for patients who are new to biologic therapies, or those who have not responded adequately to previous advanced therapies."
About the VIVID-1 Clinical Trial Program
VIVID-1 was a Phase 3, randomized, double-blind, treat-through study that evaluated the safety and efficacy of mirikizumab compared with placebo and an active control (ustekinumab) in adults with moderately to severely active CD. Patients randomized to mirikizumab were administered 900 mg of mirikizumab intravenously every four weeks from Weeks 0-8, then 300 mg subcutaneously every four weeks from Weeks 12-52. In this study, 49% of patients treated with mirikizumab or placebo had experienced a prior biologic failure. 2
The overall safety profile of mirikizumab in patients with moderately to severely active CD was consistent with the known safety profile in patients with UC. The frequency of serious adverse events was greater in placebo than mirikizumab. The most common adverse events were upper respiratory tract infections, injection site reactions, headache, and rash. 1
About Omvoh ®
Omvoh ® (mirikizumab) is an interleukin-23p19 (IL-23) antagonist indicated for the treatment of moderately to severely active UC and CD in adults. Omvoh ® selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to overactivation of the IL-23 pathway plays a critical role in the pathogenesis of CD, a chronic, IBD associated with progressive bowel damage, disability and decreased health-related quality of life.
For more information about Omvoh ®, please refer to the product monograph on Lilly.ca.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. Lilly has been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Lilly's Canadian Affiliate, Eli Lilly Canada Inc. was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world's first commercially available insulin.
Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
To learn more about Lilly Canada, visit Lilly.com/en-CA, or follow us on LinkedIn.
Omvoh ® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BC Association of Clinical Counsellors (BCACC) records 10,000 members
BC Association of Clinical Counsellors (BCACC) records 10,000 members

Cision Canada

time43 minutes ago

  • Cision Canada

BC Association of Clinical Counsellors (BCACC) records 10,000 members

More Registered Clinical Counsellors (RCCs) are expected to address growing demand for mental health services in BC VICTORIA, BC , July 24, 2025 /CNW/ - Memberships to the BC Association of Clinical Counsellors (BCACC) have crossed 10,000, marking a significant step towards addressing the growing demand for mental health services in the province. "Access to mental health care can change lives, and it starts with people who care deeply," said Amna Shah , Parliamentary Secretary for Mental Health and Addictions. "Reaching 10,000 members is a powerful milestone for the BC Association of Clinical Counsellors and a reflection of their commitment to walking alongside people on their healing journeys. Thank you for the care, strength, and hope you bring to communities across the province." Currently, the association's Registered Clinical Counsellors (RCCs) comprise 90% of clinical counsellors and psychotherapists in BC, making it the largest association for the profession. Since its formation in 1988, the association has advocated for improved public access to mental health care and enhanced public protection. To earn the title of Registered Clinical Counsellor (RCC), members must meet rigorous academic, clinical, and professional standards and commit to upholding BCACC's standards of practice and code of ethics. BCACC members also include over 1,000 student members. BCACC CEO, Michael Radano says "This milestone reflects the strong and growing professional community of psychotherapists in BC, and that clinical counselling and psychotherapy is a trusted and essential service for British Columbians. We hope that this continued growth helps to make mental health services more accessible in BC. I would like to congratulate the members, our board, and staff on this achievement. We look forward to collaborating with partner associations, organisations, and governments and lending our expertise as we move towards regulation" A rising demand for mental health services 5.7 million people call British Columbia home. According to the Canadian Mental Health Association (CMHA), by age 40, 50% of the population will have experienced a mental illness, and 1 in 5 experience mental health problems annually. The incidence of mental health issues has also been rising, particularly since the COVID-19 pandemic. It is estimated that approximately 1.25 million British Columbians may seek psychotherapy or clinical counselling annually. Many individuals face long wait times, cost restrictions, and insufficient coverage. The addition of more RCCs is expected to bridge this gap and address the growing demand for quality mental health services. The BCACC engages its membership to educate the public on mental health through free public presentations called 'Matters of the Mind' on a variety of topics aimed at increasing knowledge and awareness. Additionally, BCACC's 'Find a Counsellor' tool allows the public to find a suitable clinician by filtering for modality, gender, cultural background, specializations, availability, session style, and more. The tool currently records approximately 125,000 visits a year. In addition, the association maintains a public registry, publishes public notifications, and has a detailed inquiry process to protect the public and maintain accountability. The BCACC is currently preparing for its annual conference scheduled from September 19-20, 2025 in Vancouver. BCACC: The BC Association of Clinical Counsellors (BCACC) is a not-for-profit provincial professional association founded in 1988 with more than 10,000 members. BCACC advocates for the clinical counselling/psychotherapy profession and public access to mental health services. Its 9000+ Registered Clinical Counsellors (RCCs) are held to the highest standards of practice and a strict code of ethics in service and protection of the public which includes a robust complaint, inquiry, and remedial process. SOURCE BC Association of Clinical Counsellors For media enquiries, contact Joshua Karunakaran: Manager - PR & Communications, [email protected]

Pura Scents recalling diffusers in U.S. and Canada as magnet issue may cause ingestion hazard
Pura Scents recalling diffusers in U.S. and Canada as magnet issue may cause ingestion hazard

Toronto Sun

time2 hours ago

  • Toronto Sun

Pura Scents recalling diffusers in U.S. and Canada as magnet issue may cause ingestion hazard

Published Jul 24, 2025 • 1 minute read Pura 4 Smart Home Fragrance Diffuser is pictured in this photo provided by Health Canada. Photo by Health Canada. Pura Scents is recalling more than 850,000 diffusers because some magnets may detach and cause a possible ingestion hazard to children. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account The company is recalling about 851,400 Pura 4 Smart Home Fragrance Diffusers with detachable covers. It said an additional 1,100 were sold in Canada. Pura Scents said that the magnets on the inside cover of the product can detach, posing an ingestion hazard to children. When high-powered magnets are swallowed, the ingested magnets can attract each other, or other metal objects, and become lodged in the digestive system. This can result in perforations, twisting or blockage of the intestines, infection, blood poisoning and death. The company has received three reports of magnets detaching from the cover. No injuries have been reported. The diffusers were sold at Target, Scheels and other stores nationwide from August 2023 through May 2025 for about $50. They were also sold online through Pura's website, as well as online at Amazon, Target and Scheels. Pura Scents is offering a free replacement cover. Consumers are advised to immediately dispose of the existing detachable cover and to keep the diffusers out of the reach of children and pets. To receive the free replacement cover, individuals may contact Pura Scents at 855-394-5292 from 9 a.m. to 5 p.m. MT Monday through Friday. The company can also be emailed at replacement↕ Consumers may also visit the company's website and click on 'Recall' at the bottom of the page for more information. Sports Ontario Golf Canada Canada

Pramana Receives Health Canada Authorization for Digital Pathology Scanners
Pramana Receives Health Canada Authorization for Digital Pathology Scanners

National Post

time5 hours ago

  • National Post

Pramana Receives Health Canada Authorization for Digital Pathology Scanners

Article content CAMBRIDGE, Mass. — Pramana, an AI-enabled health tech company modernizing the pathology sector, today announced it has received Health Canada Medical Device Licenses for its flagship digital pathology scanners, the SpectralM and SpectralHT Cubiq systems. The approval authorizes Pramana to import, market, and sell its devices in Canada, expanding access to its advanced imaging and workflow solutions. Article content Health Canada authorization is required to commercialize Class II medical devices and affirms the product's safety, effectiveness, and quality. The approval opens the door for Pramana to support Canadian hospitals, pathology labs, and research institutions, helping modernize diagnostic workflows with scalable, AI-powered digital pathology tools. This recognition marks a critical step in Pramana's international expansion, building on its growing regulatory footprint. Article content 'Receiving Health Canada authorization is a major milestone in our commercialization strategy,' said Prasanth Perugupalli, Chief Product Officer at Pramana. 'It reflects the strength of our product development, quality, and regulatory readiness, and it opens the door to expanding access to our technology in a market known for strong clinical and academic institutions.' Article content Pramana's scanners are designed to digitize a wide range of pathology slides, producing high-resolution whole-slide images with automated quality control and AI-powered decision support. The platform supports both FFPE tissue and Liquid Based Cytology (LBC) samples prepared using methods such as the ThinPrep® Pap test (Hologic) and BD SurePath™ (Becton Dickinson). Unlike most digital pathology systems focused solely on anatomic pathology, Pramana expands digital workflows to include hematopathology, microbiology, and cytology, delivering flexibility across all major slide types. Article content 'Our research at the University of Toronto highlights the need for adaptable platforms that can manage these technical demands while still supporting routine histology and cytology workflows,' said Dr. Carlo Hojilla, Consultant Pathologist at the University of Toronto. 'Pramana's technology meets that standard, and its Health Canada authorization reflects both its clinical utility and the rigorous quality required for widespread adoption.' Article content Prior to receiving Health Canada authorization, Pramana secured Medical Device Single Audit Program (MDSAP) certification, a requirement that validated its quality management system and streamlined regulatory access in Canada, the United States, Brazil, Australia, and Japan, highlighting Pramana's commitment to modernizing digital pathology worldwide. Article content To discover how Pramana's whole-slide imaging solution can help healthcare organizations across Canada, visit Article content About Pramana, Inc. Article content Pramana is a health tech company transforming digital pathology with AI-powered imaging solutions that support seamless adoption across labs, health systems, and medical centers. Pramana's Spectral scanners deliver industry-leading image quality and unprecedented accuracy. Built-in AI algorithms and automated quality control streamline workflows, increase efficiency, and capture previously undetectable tissue features, empowering pathologists with the tools needed to improve clinical diagnostics and research. The company is headquartered in Cambridge, Mass. For more information, visit Article content Article content Article content Article content Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store